Sign up
Pharma Capital

Physiomics technology to be used to analyse Bicycle Therapeutics and Cancer Research UK cancer study

The AIM-listed group’s technology will be used analyse clinical data for a CRUK-sponsored phase I/IIa clinical trial of Bicycle’s BT1718 treatment for solid tumours
virtual tumour
Physiomics is the developer of the virtual tumour software platform

Physiomics Plc (LOB:PYC), developer of the virtual tumour software platform, has landed a deal with Bicycle Therapeutics and Cancer Research UK (CRUK).

The AIM-listed group’s technology will be used analyse clinical data for a CRUK-sponsored phase I/IIa clinical trial of Bicycle’s BT1718  treatment for solid tumours.

"We are very pleased to be working on this second project with Bicycle Therapeutics and to be working for the first time directly with Cancer Research UK, the UK's leading cancer research charity,” said Physiomics chief executive, Jim Millen.

The financial details are unknown.

Ian_55ae0ddd437b7.jpg
Why Invest In Physiomics Plc? Read More Here

Register here to be notified of future PYC Company articles
View full PYC profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.